August 2024

Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a clinically meaningful reduction of 38% vs. placebo (p<0.0001)1Fabhalta is an inhibitor of the alternative complement pathway, activation of whi

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: